TCR-T-话题@MedSci

#TCR-T#

12篇内容 | 793人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1510802, encodeId=0bd61510802ab, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=肿瘤免疫中TCR-T细胞治疗的研究进展, objectType=article, longId=734444, objectId=7e2ee34444b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e2ee34444b0, replyNumber=0, likeNumber=48, createdTime=2022-08-06, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e2ee34444b0, moduleTitle=肿瘤免疫中TCR-T细胞治疗的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e2ee34444b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510801, encodeId=f8e0151080141, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc., objectType=article, longId=218899, objectId=169221889999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=169221889999, replyNumber=0, likeNumber=35, createdTime=2021-10-21, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=169221889999, moduleTitle=Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc., moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=169221889999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510800, encodeId=a00a1510800fb, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=李懿点评 | TCR-T细胞疗法，三大障碍有待突破, objectType=article, longId=200496, objectId=598f20049681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=598f20049681, replyNumber=0, likeNumber=51, createdTime=2020-09-11, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=598f20049681, moduleTitle=李懿点评 | TCR-T细胞疗法，三大障碍有待突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=598f20049681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510799, encodeId=f47e1510e99d1, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线, objectType=article, longId=186503, objectId=f6d21865035f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6d21865035f, replyNumber=0, likeNumber=49, createdTime=2020-01-20, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6d21865035f, moduleTitle=新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6d21865035f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510798, encodeId=1d4c1510e98db, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器, objectType=article, longId=177005, objectId=aca81e700547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aca81e700547, replyNumber=0, likeNumber=46, createdTime=2019-08-08, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aca81e700547, moduleTitle=TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aca81e700547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510797, encodeId=fb931510e97f6, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=重磅！2017（第三届）下一代CAR&TCR-T研讨会即将召开, objectType=article, longId=114813, objectId=af551148136e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af551148136e, replyNumber=0, likeNumber=63, createdTime=2017-10-01, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af551148136e, moduleTitle=重磅！2017（第三届）下一代CAR&TCR-T研讨会即将召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af551148136e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510796, encodeId=1ccf1510e967a, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=盖茨基金会投资4000万美元支持TCR-T疗法, objectType=article, longId=113522, objectId=2b0111352213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b0111352213, replyNumber=0, likeNumber=46, createdTime=2017-09-22, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b0111352213, moduleTitle=盖茨基金会投资4000万美元支持TCR-T疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b0111352213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510795, encodeId=adb31510e956f, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=综述：CAR-T疗法、TCR-T疗法研发格局, objectType=article, longId=87275, objectId=13948e275d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13948e275d4, replyNumber=0, likeNumber=43, createdTime=2017-01-13, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13948e275d4, moduleTitle=综述：CAR-T疗法、TCR-T疗法研发格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13948e275d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510794, encodeId=c9121510e9451, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=2016 下一代CAR&TCR-T研讨会, objectType=article, longId=73173, objectId=2558e3173ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2558e3173ec, replyNumber=0, likeNumber=40, createdTime=2016-09-22, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2558e3173ec, moduleTitle=2016 下一代CAR&TCR-T研讨会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2558e3173ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510793, encodeId=f2a11510e9351, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=癌症免疫细胞治疗知识：CAR-T与TCR-T的区别在哪里？, objectType=article, longId=67381, objectId=24f76e3810f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24f76e3810f, replyNumber=0, likeNumber=47, createdTime=2016-05-03, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24f76e3810f, moduleTitle=癌症免疫细胞治疗知识：CAR-T与TCR-T的区别在哪里？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24f76e3810f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510792, encodeId=59221510e9204, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=J Immunol：CAR-T和TCR-T的前景与挑战, objectType=article, longId=55610, objectId=a6b655610ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6b655610ca, replyNumber=0, likeNumber=39, createdTime=2015-09-03, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6b655610ca, moduleTitle=J Immunol：CAR-T和TCR-T的前景与挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6b655610ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1510791, encodeId=cf861510e9112, content=<a href='/topic/show?id=cfc41e2118a' target=_blank style='color:#2F92EE;'>#TCR-T#</a>, objectTitle=CAR-T和TCR-T 在肿瘤领域应用前景和挑战, objectType=article, longId=54072, objectId=d61a540e292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d61a540e292, replyNumber=0, likeNumber=42, createdTime=2015-07-29, rootId=0, userName=wenzhiren, userId=bc0210252514, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d61a540e292, moduleTitle=CAR-T和TCR-T 在肿瘤领域应用前景和挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d61a540e292)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TCR-T

2020-05-29

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

肿瘤免疫中TCR-T细胞治疗的研究进展

2022-08-06

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

Treadwell Therapeutics宣布收购专注于新型TCR-T细胞疗法的TIO Bioventures投资组合公司TCRyption Inc.

2021-10-21

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

李懿点评 | TCR-T细胞疗法，三大障碍有待突破

2020-09-11

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

新上市的BioNTech收购Neon以增强其CAR-T和TCR-T细胞治疗管线

2020-01-20

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器

2019-08-08

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

重磅！2017（第三届）下一代CAR&TCR-T研讨会即将召开

2017-10-01

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

盖茨基金会投资4000万美元支持TCR-T疗法

2017-09-22

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

综述：CAR-T疗法、TCR-T疗法研发格局

2017-01-13

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

2016 下一代CAR&TCR-T研讨会

2016-09-22

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

癌症免疫细胞治疗知识：CAR-T与TCR-T的区别在哪里？

2016-05-03

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

J Immunol：CAR-T和TCR-T的前景与挑战

2015-09-03

wenzhiren (审核中...)

前往app查看评论内容

#TCR-T#

CAR-T和TCR-T 在肿瘤领域应用前景和挑战

2015-07-29

科室
- - 订阅+
  - 更多科室
工具
服务